Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
NLRC4-mediated activation of CD1c+ DC contributes to perpetuation of synovitis in rheumatoid arthritis
Cristina Delgado-Arévalo, … , Isidoro González Álvaro, Enrique Martin-Gayo
Cristina Delgado-Arévalo, … , Isidoro González Álvaro, Enrique Martin-Gayo
Published October 4, 2022
Citation Information: JCI Insight. 2022;7(22):e152886. https://doi.org/10.1172/jci.insight.152886.
View: Text | PDF
Research Article Cell biology

NLRC4-mediated activation of CD1c+ DC contributes to perpetuation of synovitis in rheumatoid arthritis

  • Text
  • PDF
Abstract

The individual contribution of specific myeloid subsets such as CD1c+ conventional DC (cDC) to perpetuation of rheumatoid arthritis (RA) pathology remains unclear. In addition, the specific innate sensors driving pathogenic activation of CD1c+ cDC in patients with RA and their functional implications have not been characterized. Here, we assessed phenotypical, transcriptional, and functional characteristics of CD1c+ and CD141+ cDC and monocytes from the blood and synovial fluid of patients with RA. Increased levels of CCR2 and the IgG receptor CD64 on circulating CD1c+ cDC was associated with the presence of this DC subset in the synovial membrane in patients with RA. Moreover, synovial CD1c+ cDC are characterized by increased expression of proinflammatory cytokines and high abilities to induce pathogenic IFN-γ+IL-17+CD4+ T cells in vitro. Finally, we identified the crosstalk between Fcγ receptors and NLRC4 as a potential molecular mechanism mediating pathogenic activation, CD64 upregulation, and functional specialization of CD1c+ cDC in response to dsDNA-IgG in patients with RA.

Authors

Cristina Delgado-Arévalo, Marta Calvet-Mirabent, Ana Triguero-Martínez, Enrique Vázquez de Luis, Alberto Benguría-Filippini, Raquel Largo, Diego Calzada-Fraile, Olga Popova, Ildefonso Sánchez-Cerrillo, Ilya Tsukalov, Roberto Moreno-Vellisca, Hortensia de la Fuente, Gabriel Herrero-Beaumont, Almudena Ramiro, Francisco Sánchez-Madrid, Santos Castañeda, Ana Dopazo, Isidoro González Álvaro, Enrique Martin-Gayo

×

Figure 1

Alterations in frequencies and expression of CD64 in DC subsets present in peripheral blood and synovial fluid from patients with RA.

Options: View larger image (or click on image) Download as PowerPoint
Alterations in frequencies and expression of CD64 in DC subsets present ...
(A and B) Analysis of DAS28-ESR and number of swollen joint count (SJC) (A) or proportions of CD1c+ cDC (B) in blood samples from n = 31 patients with RA collected at the first visit (untreated baseline) and after 1 or 2 years of treatment. Statistical significance was calculated using a 2-tailed matched-pairs Wilcoxon test. (C) Proportions of CD40 (left), CD64 (center), and CD16 (right) on gated CD1c+ cDC (upper plots) and CD141+ cDC (lower plots) from the blood of healthy controls (HC, n = 28) and untreated patients with RA (n = 31) and SF from treated patients with RA (n = 12). Statistical significance was calculated using a Kruskal-Wallis test with Dunn’s correction. (D) Proportions of CD64+ cells within circulating CD1c+ cDC from the blood of n = 19 HC and n = 14 patients with RA at baseline and 1–2 years after treatment initiation. Statistical significance was calculated using a 2-tailed Mann Whitney U test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts